U.S. Stock Market Midday Update
OSR fell 19.19%, with increased trading volume. Based on recent news,
<ol>
<li>
On May 6, OSR Holdings announced its latest financial status and future development plans. After the announcement, market concerns about the company's prospects led to a significant drop in stock price.
</li>
<li>
On May 5, Emerging Growth Research released a report reiterating a buy rating for OSR Holdings, setting a target price of $10. However, the market's reaction to this rating was below expectations, and the stock price continued to decline.
</li>
<li>
No other significant news recently. Market concerns about the company's prospects have led to stock price volatility.
</li>
</ol>
Top Stocks by Industry Trading Volume
Gilead Sciences fell 2.57%. Based on recent key news:
<ol>
<li>
On May 7, Gilead Sciences reported first-quarter results, and although earnings exceeded expectations, the full-year non-GAAP earnings per share guidance was adjusted from profit to loss, causing the stock price to drop about 2%. The company expects non-GAAP earnings per share for 2026 to be between -$1.05 and -$1.65, a significant downward adjustment from the previous $8.45 to $8.85. This change is primarily due to acquisition-related expenses. Source: Reuters
</li>
<li>
On May 8, Gilead Sciences announced a 54% year-over-year increase in quarterly net profit, but due to the acquisition of cell therapy company Arcellx, the full-year sales forecast was raised, while the earnings per share loss forecast was set at $0.65 to $1.05, leading to a negative market reaction. Source: Zhitong Finance
</li>
<li>
On May 8, analysts lowered the median estimate for Gilead Sciences' 2026 earnings per share from $8.63 to -$0.72, reflecting market concerns about the company's future profitability. Source: FactSet The biotechnology industry is facing intensified competition and significant capital outflows.
</li>
</ol>
Moderna rose 17.20%. Based on recent news,
<ol>
<li>
On May 8, Moderna's stock price rose 16%, reaching a nearly one-month high. Analysts believe this is related to hantavirus. Moderna signed a collaboration agreement with a South Korean university to develop an mRNA-based hantavirus vaccine. Nevertheless, Evercore analysts stated that the hantavirus market is small, and the current stock price increase is more sentiment-driven. Source: Reuters
</li>
<li>
On May 8, news of a hantavirus outbreak on a cruise ship drew market attention. The World Health Organization confirmed that as of May 4, there were 7 reported cases of hantavirus and 3 deaths on the cruise ship. Moderna's candidate vaccine is still in the preclinical stage, and analysts pointed out that the current stock price surge is more speculative trading. Source: Wall Street Insight
</li>
<li>
On May 7, Moderna's stock price briefly soared to $52 in early trading on Thursday but then retreated. Analysts noted that the hantavirus vaccine is still several years away from market launch, and the current stock price increase lacks fundamental support
Source: MarketWatch The hantavirus vaccine market size is small, with significant emotional drivers.
</li>
</ol>
Insmed fell 4.03%, with increased trading volume. Based on recent key news:
<ol>
<li>
On May 7, Insmed reported a net loss of $163.6 million for the first quarter, narrowing from $256.6 million in the same period last year, with product revenue significantly increasing to $305.96 million. Despite the improvement in financial performance, the stock price still dropped 5.15% in pre-market trading. Source: RTTNews
</li>
<li>
On May 7, Insmed's new lung drug Brinsupri performed poorly, failing to meet buyer expectations, leading to a significant drop in stock price. Nevertheless, analysts remain optimistic about the company's prospects. Source: RTTNews
</li>
<li>
On May 8, analysts lowered their EPS estimates for Insmed for 2026, with a target price of $212, which is 54.6% higher than the closing price on May 6. Analysts maintain a buy rating. Source: FactSet The pharmaceutical industry has been volatile recently and requires attention.
</li>
</ol>
Stocks ranked at the top of the industry market capitalization
AbbVie fell 0.95%, with increased trading volume. Based on recent key news:
<ol>
<li>
On May 8, AbbVie announced in the EDGAR system the disclosure of the company's financial and business development status, showing strong sales growth and increased R&amp;D investment, boosting market confidence.
</li>
<li>
On May 6, analyst ratings indicated that AbbVie rose 9 places in the S&amp;P 500 index, reflecting market optimism about its prospects.
</li>
<li>
On May 6, AbbVie announced it would participate in the Bank of America Securities Healthcare Conference on May 13, where management will hold a fireside chat, potentially providing more information on business development. The pharmaceutical industry has shown stable performance recently, with increased R&amp;D investment
</li>
</ol>

OSRH

OSR fell 19.19%; Gilead Sciences fell 2.57%, with a transaction volume of USD 644 million; Moderna rose 17.20%, with a transaction volume of USD 611 million; Insmed fell 4.03%, with a transaction volume of USD 416 million; AbbVie fell 0.95%, with a market capitalization of USD 355.4 billion

Price Alert

U.S. stock market update: OSR Holdings down 19.19%, financial concerns suppress market reaction, buy rating fails to boost stock price